Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Vical
company
About
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies.
- 251 - 500
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- $2.50M
- Industries
- Biotechnology,Genetics
- Founded date
- Jan 1, 1987
- Number Of Employee
- 251 - 500
- Operating Status
- Active
Vical's core technology grew out of a chance discovery and provided the cornerstones for two new biopharmaceutical industry sectors: DNA vaccines and non-viral gene therapy. Vical's management systematically leveraged that technology into a broad portfolio of independent and partnered product development programs. The first products for animal health are on the market. The first human products are approaching.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$2.50M
Vical has raised a total of
$2.50M
in funding over 2 rounds. Their latest funding was raised on
Sep 29, 1988 from a Series Unknown round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 29, 1988 | Series Unknown | $2.50M | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
Vical is funded by 2 investors.
Sequoia Capital
and Security Pacific Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Sequoia Capital
|
— | Series Unknown |
|
|
— | Series Unknown |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
